Sometimes in dealmaking, the numbers just don't work. Merck & Co., Inc. (MRK) has reportedly walked away from talks to acquire cancer drug developer Revolution Medicines, Inc. (RVMD) after the two sides couldn't bridge the gap on valuation, according to a Wall Street Journal report on Sunday.

The deal collapse marks a sharp reversal from earlier in January, when the Financial Times reported that Merck was in discussions to acquire Revolution Medicines in a transaction potentially valued between $28 billion and $32 billion. The talks had centered around a roughly $30 billion valuation, but citing people familiar with the matter, the Journal's report signals that Merck continues to exercise discipline on deal size even as it pursues high-growth oncology assets.

Sticking to the Strategy

Merck CEO Robert Davis laid out the company's acquisition playbook earlier this month at the J.P. Morgan Healthcare Conference. He said Merck has primarily been targeting deals valued at $15 billion or less, though the company remains open to larger transactions under the right conditions. Apparently, Revolution Medicines didn't meet those conditions at the price being discussed.

Revolution Medicines wasn't short on suitors, either. Earlier in January, AbbVie Inc. (ABBV) was also reportedly in advanced talks to buy the cancer biotech, though details remained sparse. Shortly after those reports surfaced, the company told Reuters it "is not in discussions with Revolution Medicines."

From $16 Billion to $22 Billion and Back Down

Before acquisition chatter heated up earlier in 2026, Revolution Medicines carried a market value of about $16 billion. Its shares surged following the deal speculation, briefly pushing the company's valuation above $22 billion. That's quite a pop, and it helps explain why finding agreement on price became tricky.

What makes Revolution Medicines so attractive? The company is developing targeted cancer therapies focused on the RAS molecular driver, a pathway that has long been considered extremely difficult to drug. According to Mizuho Securities cited in the Wall Street Journal report, Revolution Medicines' experimental pancreatic cancer treatment alone could generate as much as $10 billion in annual sales by 2035. That's the kind of blockbuster potential that gets pharma giants interested.

What Comes Next

Just because the talks fell apart doesn't mean the story is over. People familiar with the discussions indicated that talks could potentially restart, or another bidder could emerge. In biotech M&A, these things have a way of cycling back around when the fundamentals are strong and the strategic fit makes sense.

Investor attention is now building ahead of upcoming clinical updates. Revolution Medicines is expected to release closely watched trial data for its pancreatic and colorectal cancer drug candidates in the first half of this year. Those results could be a major catalyst one way or another, potentially reigniting deal interest or giving the company ammunition to stand alone.

The company has serious momentum in its pipeline. In October 2025, Revolution Medicines' daraxonrasib (RMC-6236) for pancreatic cancer was included in the FDA's Commissioner's National Priority Voucher program. That's a notable validation of the drug's potential.

Daraxonrasib is currently being studied in two global Phase 3 clinical trials. The first, RASolute 302, is testing the drug in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The second, RASolve 301, is evaluating it in patients with previously treated metastatic non-small cell lung cancer. These are large, difficult-to-treat patient populations where new options are desperately needed.

Market Reaction

Price Action: Revolution Medicines shares were down 22.74% at $90.88 during premarket trading on Monday. Merck shares were up 0.15% at $108.34.